MedPath

Analysis of the Electroencephalogram (EEG) during anesthesia using remimazolam and remifentanil

Not Applicable
Conditions
External causes of morbidity and mortality
Registration Number
KCT0006846
Lead Sponsor
Asan Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

1.Patients between 20 and 80 years of age
2.A patient scheduled for regular surgery under general anesthesia in the operating room E rosette of Asan Medical Center, Seoul
3.Patients belonging to the American Society of Anesthesiology Classification 1, 2, or 3
4. Those who voluntarily agreed in writing to participate in this clinical study

Exclusion Criteria

1. Cardiovascular disease, respiratory disease, kidney disease, endocrine disease, blood disease (hemorrhagic predisposition), central nervous system disease, mental disease, Or if there is a history of meningitis or other abnormalities (refer to laboratory test values)
2. After taking central nervous system drugs (ketamine, amphetamine, midazolam, opioid, chlorpromazine, clozapine, olanzapine, risperidone, haloperidol, quetiapine, risperidone, paliperidone, amisulpride, sertindole), the elimination half-life of each drug multiplied by 5 patient
3. Patients judged inappropriate by other researchers

Study & Design

Study Type
Observational Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Calculation of Approximate Entropy for EEG Changes Following Remimazolam Administration;Frequency analysis (Fourier transform and bispectral analysis) for EEG changes following remimazolam administration
Secondary Outcome Measures
NameTimeMethod
The correlation between the bispectral index, brain anesthesia response monitoring index, and changes in the patient's level of consciousness according to the administration of remimazolam
© Copyright 2025. All Rights Reserved by MedPath